MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
MaxCyte celebrates its 25th anniversary as a pioneer in non-viral cell engineering technologies. The company's Flow Electroporation® technology played a important role in developing CASGEVY®, the first FDA-approved non-viral cell therapy, in collaboration with Vertex Pharmaceuticals and CRISPR Therapeutics. MaxCyte has established 29 Strategic Platform License agreements across various therapeutic areas.
In 2022, the company relocated to a 67,000 square-foot facility in Maryland's I-270 biotech corridor, expanding its manufacturing capacity and research capabilities. Under CEO Maher Masoud's leadership, MaxCyte continues to advance its proprietary ExPERT™ platform, supporting customers in developing next-generation cell therapeutics.
MaxCyte celebra il suo 25° anniversario come pioniere nelle tecnologie di ingegneria cellulare non virali. La tecnologia Flow Electroporation® dell'azienda ha svolto un ruolo importante nello sviluppo di CASGEVY®, la prima terapia cellulare non virale approvata dalla FDA, in collaborazione con Vertex Pharmaceuticals e CRISPR Therapeutics. MaxCyte ha stabilito 29 accordi di licenza su piattaforma strategica in vari ambiti terapeutici.
Nel 2022, l'azienda si è trasferita in una struttura di 67.000 piedi quadrati nel corridoio biotecnologico I-270 del Maryland, ampliando la propria capacità di produzione e le capacità di ricerca. Sotto la guida del CEO Maher Masoud, MaxCyte continua a sviluppare la propria piattaforma proprietaria ExPERT™, supportando i clienti nello sviluppo di terapie cellulari di nuova generazione.
MaxCyte celebra su 25° aniversario como pionero en tecnologías de ingeniería celular no viral. La tecnología Flow Electroporation® de la compañía desempeñó un papel importante en el desarrollo de CASGEVY®, la primera terapia celular no viral aprobada por la FDA, en colaboración con Vertex Pharmaceuticals y CRISPR Therapeutics. MaxCyte ha establecido 29 acuerdos de Licencia de Plataforma Estratégica en diversas áreas terapéuticas.
En 2022, la compañía se trasladó a una instalación de 67,000 pies cuadrados en el corredor biotecnológico I-270 de Maryland, ampliando su capacidad de fabricación y sus capacidades de investigación. Bajo el liderazgo del CEO Maher Masoud, MaxCyte continúa avanzando en su plataforma propietaria ExPERT™, apoyando a los clientes en el desarrollo de terapias celulares de próxima generación.
맥사이티는 비바이러스 세포 공학 기술의 선구자로서 25주년을 기념합니다. 이 회사의 Flow Electroporation® 기술은 Vertex Pharmaceuticals 및 CRISPR Therapeutics와 협력하여 FDA 승인을 받은 최초의 비바이러스 세포 치료제인 CASGEVY® 개발에 중요한 역할을 했습니다. 맥사이티는 다양한 치료 분야에서 29개의 전략적 플랫폼 라이센스 계약을 체결했습니다.
2022년, 이 회사는 메릴랜드의 I-270 생명공학 회랑에 67,000 평방피트 규모의 시설로 이전하여 제조 능력과 연구 능력을 확장했습니다. CEO Maher Masoud의 지도 아래, 맥사이티는 차세대 세포 치료제를 개발하는 고객을 지원하는 독자적인 ExPERT™ 플랫폼을 계속 발전시키고 있습니다.
MaxCyte célèbre son 25e anniversaire en tant que pionnier des technologies d'ingénierie cellulaire non virale. La technologie Flow Electroporation® de l'entreprise a joué un rôle clé dans le développement de CASGEVY®, la première thérapie cellulaire non virale approuvée par la FDA, en collaboration avec Vertex Pharmaceuticals et CRISPR Therapeutics. MaxCyte a établi 29 accords de licence de plateforme stratégique dans divers domaines thérapeutiques.
En 2022, l'entreprise a déménagé dans une installation de 67 000 pieds carrés dans le couloir biotechnologique I-270 du Maryland, élargissant sa capacité de production et ses capacités de recherche. Sous la direction du PDG Maher Masoud, MaxCyte continue de faire progresser sa plateforme exclusive ExPERT™, soutenant ses clients dans le développement de thérapies cellulaires de nouvelle génération.
MaxCyte feiert sein 25-jähriges Bestehen als Pionier in der nicht-viralen Zelltechnik. Die Flow Electroporation®-Technologie des Unternehmens spielte eine wichtige Rolle bei der Entwicklung von CASGEVY®, der ersten von der FDA zugelassenen nicht-viralen Zelltherapie, in Zusammenarbeit mit Vertex Pharmaceuticals und CRISPR Therapeutics. MaxCyte hat 29 strategische Plattformlizenzvereinbarungen in verschiedenen therapeutischen Bereichen etabliert.
Im Jahr 2022 zog das Unternehmen in eine 67.000 Quadratfuß große Einrichtung im Biotech-Korridor I-270 in Maryland um und erweiterte seine Produktionskapazität und Forschungskompetenz. Unter der Leitung von CEO Maher Masoud setzt MaxCyte die Weiterentwicklung seiner proprietären ExPERT™-Plattform fort, um Kunden bei der Entwicklung der nächsten Generation von Zelltherapeutika zu unterstützen.
- None.
- None.
Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year. Over the past quarter-century, the company has remained steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health.
“Since the Company’s inception, MaxCyte set out to commercialize Flow Electroporation® technology with a talented global team and, over the years, we have developed and launched a suite of products within our proprietary ExPERT™ platform,” said Maher Masoud, President and CEO of MaxCyte. “Today, we are proud to provide our customers with best-in-class electroporation solutions and tools. Knowing that our customers and their patients come first drives us to find the solutions to meet their needs as we enter the next era of scientific discovery and development focused on cell and gene therapy.”
MaxCyte’s Flow Electroporation technology was used to support the development of CASGEVY®, the industry’s first, FDA-approved, non-viral cell therapy. Under Strategic Platform License (SPL) agreements, the company worked with Vertex Pharmaceuticals and CRISPR Therapeutics on this first-of-its-kind CRISPR/Cas9 genome-edited cell therapy. In total, MaxCyte has signed 29 SPL agreements with cell therapy developers across a broad spectrum of therapeutic areas.
To continue supporting its customers in their journey through therapeutic development to commercialization, in 2022 MaxCyte moved to its present headquarters, a 67,000 square-foot facility located in Maryland’s I-270 biotech corridor, which significantly increased the Company’s in-house manufacturing capacity, as well as research and process development lab space.
“We've made tremendous progress over the last 25 years,” added Masoud. “As advanced cell and gene therapy therapeutic modalities move from concept to clinic, new cell engineering approaches will continue to emerge and mature. With every milestone, we are able to leverage our best-in-class electroporation technology and experience in the industry to support our customers in pushing the frontiers of bio-based medicines to improve patients’ lives.”
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Science
Jordan Vines
+1 540-629-3137
jvines@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Healthcare
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.
Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 12, 2024, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
FAQ
What major milestone did MaxCyte (MXCT) achieve with CASGEVY therapy in 2024?
How many Strategic Platform License (SPL) agreements does MaxCyte (MXCT) currently have?
When did MaxCyte (MXCT) move to its new headquarters and what are its features?
What is MaxCyte's (MXCT) core technology platform?
